• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529

tetano

Editor, Senior Moderator
Cell Rep


. 2022 May 20;110924.
doi: 10.1016/j.celrep.2022.110924. Online ahead of print.
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529


Qian Wang[SUP] 1 [/SUP], Saumya Anang[SUP] 2 [/SUP], Sho Iketani[SUP] 3 [/SUP], Yicheng Guo[SUP] 3 [/SUP], Lihong Liu[SUP] 3 [/SUP], Phinikoula S Katsamba[SUP] 4 [/SUP], Lawrence Shapiro[SUP] 5 [/SUP], David D Ho[SUP] 3 [/SUP], Joseph G Sodroski[SUP] 6 [/SUP]



Affiliations

Abstract

The recently emerged B.1.1.529 (Omicron) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant has a highly divergent spike (S) glycoprotein. We compared the functional properties of B.1.1.529 BA.1 S with those of previous globally prevalent SARS-CoV-2 variants, D614G and B.1.617.2. Relative to these variants, B.1.1.529 S exhibits decreases in processing, syncytium formation, virion incorporation, and ability to mediate infection of cells with high TMPRSS2 expression. B.1.1.529 and B.1.617.2 S glycoproteins bind ACE2 with higher affinity than D614G S. The unliganded B.1.1.529 S trimer is less stable at low temperatures than the other SARS-CoV-2 Ss, a property related to its more "open" S conformation. Upon ACE2 binding, the B.1.1.529 S trimer sheds S1 at 37°C, but not at 0°C. B.1.1.529 pseudoviruses are relatively resistant to neutralization by sera from patients with coronavirus disease 2019 (COVID-19) and vaccinees. These properties of the B.1.1.529 S glycoprotein likely influence the transmission, cytopathic effects, and immune evasion of this emerging variant.

Keywords: ACE2 affinity; B.1.1.529; B.1.617.2; CP: Immunology; CP: Microbiology; Omicron; S1 shedding; SARS-CoV-2; neutralization sensitivity; stability; variants.
 
Back
Top Bottom